Exelixis
Tracked across 2 events · 12 articles · First seen Jul 31, 2026 · Last active Aug 12, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Exelixis is the subject of the investigation. Its shares fell after reporting Q2 revenue below consensus and lowering full-year guidance, and it now faces potential securities litigation.
Aug 10, 2026 · 6 articles
Regulatory
Impact: Exelixis markets CABOMETYX, the reference product to which OMCAZIO is bioequivalent. The approval of a lower-dose alternative could increase competition and pressure its market share.
Jul 31, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Exelixis live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard